TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03894501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Methadone program behavioral treatment as usual
Description: In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
Study: NCT01256957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA filter
Study: NCT01666392

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00551668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal patellar surgery
Description: Initial proximal patellar surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonoperative
Description: Nonoperative without surgery
Study: NCT02268578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: 2mA tDCS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is administered but at 0mA
Study: NCT00555152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02821377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous furosemide
Description: treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous furosemide
Description: treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solutions
Description: Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solutions
Description: Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seriated paracentesis
Description: repeated paracentesis from the first day after admission until 3 days before discharge
Study: NCT02947165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
Study: NCT01794741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dymista Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate nasal spray
Study: NCT03797118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR
Description: Fractional flow reserve measured during cardiac catheterization
Study: NCT03117608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of autologous micro-fragmented adipose tissue (aMAT)
Description: adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: injection of Platelet-rich Plasma (PRP)
Description: injection of platelet-rich plasma
Study: NCT01156389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir and Pyramax
Description: 100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyramax
Description: Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
Study: NCT01524432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-fungal agent (Clotrimazole) loaded microcapsules
Description: Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug loaded microcapsules socks
Study: NCT00118352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo low-dose TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT06095349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhalatory treatment with sulfureous aerosol
Description: osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
Study: NCT03110757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
Study: NCT00555152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT03203681

Intervention type: DRUG
Group type: OTHER
Intervention: Natesto
Description: 4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
Study: NCT04419012

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT02125721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 1g per day
Description: 500mg PO BID x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 2g per day
Description: 1g PO BID x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiopronin 3g per day
Description: 1.5g PO BID x 7 days
Study: NCT00812448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tea catechin extracts
Description: catechins are composed of tea catechin extracts available in grren tea supplements
Study: NCT04028596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: once, 1000mg, 2 h before ECT session
Study: NCT04204057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib 800 mg BID, Orally
Study: NCT05395286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovation Lab
Description: An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
Study: NCT00118352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy
Description: Undergo GVHD prophylaxis/therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02049190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Study: NCT02699008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Antiplatelet agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Antiplatelet agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: New P2Y12 receptor inhibitor antiplatelet agent
Study: NCT02632201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIK-HER2
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-PMAT
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT01703117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 20-22 subjects between the ages of 60-85 will receive study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20-22 subjects between the ages of 60-85 will receive placebo
Study: NCT03469830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSCP
Description: Insert

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPMS
Description: Pressure therapy
Study: NCT04028596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotop
Description: once, 60mg, 2 h before ECT session
Study: NCT01103284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0 mg dose in 0.5 mL of solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months
Study: NCT02493608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel
Description: used to cut the abdominal wall.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: Diathermy used to cut , coagulate the tissue
Study: NCT02461355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aphasia therapy
Description: Aphasia therapy using a computerized scripting program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Aphasia therapy
Description: Aphasia therapy using a computerized scripting program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation using the Chattanooga Ionto device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation using the Chattanooga Ionto device
Study: NCT01953341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 333
Description: Oral administration available in varying dose strength.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing no active drug
Study: NCT03345667

Intervention type: DRUG
Intervention: lucentis
Description: Use of lucentis and other anti-vegf in patients with diabetic retinopathy
Study: NCT01194479

Intervention type: DRUG
Group type: OTHER
Intervention: Formoterol
Description: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Participants in both arms received placebo on 1 of the 2 visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants in both arms received placebo on 1 of the 2 visits.
Study: NCT02085785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached group
Description: Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed control group
Description: Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.

Intervention type: OTHER
Group type: OTHER
Intervention: Screened only
Description: Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
Study: NCT05547074

Intervention type: PROCEDURE
Intervention: pancreatic cancer surgery
Description: Surgical resection of pancreatic cancer，including radical or palliative surgery

Intervention type: PROCEDURE
Intervention: pancreatic cancer surgery
Description: Surgical resection of pancreatic cancer，including radical or palliative surgery
Study: NCT03430596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trihexyphenidyl hydrochloride
Description: he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
Study: NCT03454919

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance.
Study: NCT05780112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: * Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand.
Study: NCT01575496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainSTIM Transcranial Stimulator
Description: Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BrainSTIM Transcranial Stimulator
Description: Sham tDCS sessions will last 20 minutes.
Study: NCT03469830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPMS
Description: Pressure therapy
Study: NCT02993068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch genetic testing online educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch genetic testing online educational video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Watch genetic testing online educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch genetic testing online educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive post-telephone genetic counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive post-telephone genetic counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive pre-telephone genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive pre-telephone genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02542891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended CBT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Study: NCT02372708

Intervention type: DRUG
Intervention: dinitrophenyl(DNP)

Intervention type: DRUG
Intervention: dinitrophenyl(DNP)

Intervention type: RADIATION
Intervention: Radiation
Description: laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
Study: NCT02442453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of curenext gel
Description: Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
Study: NCT00592540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrelated Donor BMT
Description: Unrelated donor bone marrow transplantation has not been performed with these patients in the past
Study: NCT00794365

Intervention type: DRUG
Intervention: Varenicline
Description: There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water.
Study: NCT03403985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Description: Ca(OH)2 will be used in this group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: MTA will be used in this group